Written in Blood
Predicting Response and
Prognosis With Midostaurin in
Advanced Systemic Mastocytosis
In April 2017, the U.S. Food and
Drug Administration approved
the multitargeted KIT inhibi-
tor for the treatment of adult
patients with FLT3-positive,
newly diagnosed acute myeloid
leukemia and adults with aggres-
sive systemic mastocytosis (SM),
SM with associated hematologic
neoplasm, or mast cell leukemia.
The approval for SM was based
on results from a clinical t